Literature DB >> 4082901

Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability.

R L Sutcliffe, R Prior, B Mawby, W J McQuillan.   

Abstract

The study of a population of 208,000 in a Midlands district of England has shown the prevalence of idiopathic Parkinson's disease to be 108.4 per 100,000. This is comparable with past studies in Carlisle, England, Rochester, Minnesota, and South-West Finland. Parkinsonism associated with cerebrovascular disease is evidently recognised and differentiated by general practitioners; post-encephalitic parkinsonism is not encountered and drug-induced parkinsonism is not common in this district. The major functional disability of a carefully assessed randomly selected group was found to relate to walking and hygiene. Nevertheless, the essential physical needs of those with Parkinson's disease appear to be well met in general.

Entities:  

Mesh:

Year:  1985        PMID: 4082901     DOI: 10.1111/j.1600-0404.1985.tb00886.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  14 in total

1.  Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London.

Authors:  A Schrag; Y Ben-Shlomo; N P Quinn
Journal:  BMJ       Date:  2000-07-01

Review 2.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

4.  Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques.

Authors:  Mark J C Nuijten; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  Parkinson's disease: disability, review, and management.

Authors:  W J Mutch; A Strudwick; S K Roy; A W Downie
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

Review 6.  Health-related quality-of-life measurement in patients with Parkinson's disease.

Authors:  C Jenkinson; R Fitzpatrick; V Peto
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

7.  The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease.

Authors:  V Peto; C Jenkinson; R Fitzpatrick; R Greenhall
Journal:  Qual Life Res       Date:  1995-06       Impact factor: 4.147

8.  Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.

Authors:  Michael Iskedjian; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  The prevalence of Parkinson's disease in Portugal. A population approach.

Authors:  J A Dias; M M Felgueiras; J P Sanchez; J M Gonçalves; J M Falcäo; Z P Pimenta
Journal:  Eur J Epidemiol       Date:  1994-12       Impact factor: 8.082

10.  Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?

Authors:  Y Ben-Shlomo; M G Marmot
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.